Compounds > pyrroles
Page last updated: 2024-08-18

pyrroles and trametinib

pyrroles has been researched along with trametinib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Akiyama, R; Anderson, JL; Denny, CT; Federman, N; Park, A; Tap, WD1
Bridgeman, VL; Foo, S; Frentzas, S; Gore, M; Larkin, J; Nathan, MR; Nathan, PD; Powles, T; Preece, N; Reynolds, AR; Springer, CJ; Vasudev, NS; Vermeulen, PB; Wan, E; Welti, JC1
Adderley, T; Christopher, G; Irwin, MS; Kano, Y; Kee, L; Ladumor, Y; Ohh, M; Robinson, CM; Valencia-Sama, I1

Other Studies

3 other study(ies) available for pyrroles and trametinib

ArticleYear
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Mutation; Osteosarcoma; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Sarcoma; Signal Transduction; TOR Serine-Threonine Kinases

2015
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Endothelial Cells; Female; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Pyrroles; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays

2016
    Cancer research, 2020, 08-15, Volume: 80, Issue:16

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Heterografts; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Recurrence, Local; Neuroblastoma; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Triazoles; Vemurafenib

2020